Tafasitamab Plus Lenalidomide May Improve Overall Survival in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.